China-based Biocytogen has commenced trading on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE), becoming one of the few biotechnology companies in the industry to be listed in Hong Kong first and then in the A-share market. The company issued 47.5 million shares at a price of RMB 26.68 each, raising approximately RMB 1.3 billion (USD 180 million). Its share price opened 117% higher at RMB 58, giving it a market capitalisation exceeding RMB 25.9 billion (USD 3.7 billion). The listing, characterised by high market enthusiasm with an oversubscription rate exceeding 5,383 times, underscores investor confidence in Biocytogen's unique dual-engine technology platform and its role as an enabler for global drug discovery.

The company's core value proposition is built on its two proprietary platforms: the RenMice series of fully human antibody mice, which generate authentic human antibody sequences, and its extensive library of over 1,700-target humanised mouse models for pre-clinical evaluation. This integrated approach aims to accelerate antibody discovery and validation for partners. The strategy is commercially validated, with the company reporting robust revenue growth, particularly from overseas markets, and partnerships with nearly all of the world's top ten pharmaceutical firms, including recent collaborations with Merck and Gilead Sciences.

According to PharmCube's NextBiopharm® database, Biocytogen's pipeline comprises over 60 drug candidates, including 9 clinical assets. Click here to request a free trial for NextBiopharm®.